165 related articles for article (PubMed ID: 36832117)
1. An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples.
Bironzo P; Pepe F; Russo G; Pisapia P; Gragnano G; Aquino G; Bessi S; Buglioni S; Bartoccini F; Ferrero G; Bresciani MA; Francia di Celle P; Sibona F; Giusti A; Movilia A; Farioli RM; Santoro A; Salemi D; Scarpino S; Galafate D; Tommasi S; Lacalamita R; Seminati D; Sajjadi E; Novello S; Pagni F; Troncone G; Malapelle U
Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832117
[TBL] [Abstract][Full Text] [Related]
2. Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience.
Pepe F; Russo G; Venuta A; Scimone C; Nacchio M; Pisapia P; Goteri G; Barbisan F; Chiappetta C; Pernazza A; Campagna D; Giordano M; Perrone G; Sabarese G; Altimari A; de Biase D; Tallini G; Calistri D; Chiadini E; Capelli L; Santinelli A; Gulini AE; Pierpaoli E; Badiali M; Murru S; Murgia R; Guerini Rocco E; Venetis K; Fusco N; Morotti D; Gianatti A; Furlan D; Rossi G; Melocchi L; Russo M; De Luca C; Palumbo L; Simonelli S; Maffè A; Francia di Celle P; Venesio T; Scatolini M; Grosso E; Orecchia S; Fassan M; Balistreri M; Zulato E; Reghellin D; Lazzari E; Santacatterina M; Piredda ML; Riccardi M; Laurino L; Roz E; Longo D; Romeo DP; Fazzari C; Moreno-Manuel A; Puglia GD; Prjibelski AD; Shafranskaya D; Righi L; Listì A; Vitale D; Iaccarino A; Malapelle U; Troncone G
Oncol Ther; 2024 Mar; 12(1):73-95. PubMed ID: 38200361
[TBL] [Abstract][Full Text] [Related]
3. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples.
O'Brien O; Wright MC; O'Brien C; Geoghegan O; Leonard N; Nicholson S; Cuffe S; Fabre A; Jochum W; Joerger M; Gray SG; Finn SP
Diagnostics (Basel); 2019 Jan; 9(1):. PubMed ID: 30669306
[TBL] [Abstract][Full Text] [Related]
4. Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR.
Das R; Jakubowski MA; Spildener J; Cheng YW
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230737
[TBL] [Abstract][Full Text] [Related]
5. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
Sui JSY; Finn SP; Gray SG
Methods Mol Biol; 2021; 2279():145-155. PubMed ID: 33683691
[TBL] [Abstract][Full Text] [Related]
6. Frequency of
Champagnac A; Bringuier PP; Barritault M; Isaac S; Watkin E; Forest F; Maury JM; Girard N; Brevet M
J Thorac Dis; 2020 May; 12(5):2172-2178. PubMed ID: 32642122
[TBL] [Abstract][Full Text] [Related]
7. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
9. An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
Teishikata T; Shiraishi K; Shinno Y; Kobayashi Y; Kashima J; Ishiyama T; Yoshida T; Mori T; Yatabe Y
J Thorac Oncol; 2021 Dec; 16(12):2133-2138. PubMed ID: 34419686
[TBL] [Abstract][Full Text] [Related]
10. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
11. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
12. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
13. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
[TBL] [Abstract][Full Text] [Related]
14. DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Davies KD; Lomboy A; Lawrence CA; Yourshaw M; Bocsi GT; Camidge DR; Aisner DL
J Thorac Oncol; 2019 Apr; 14(4):737-741. PubMed ID: 30639620
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
[No Abstract] [Full Text] [Related]
16. A narrative review of MET inhibitors in non-small cell lung cancer with
Santarpia M; Massafra M; Gebbia V; D'Aquino A; Garipoli C; Altavilla G; Rosell R
Transl Lung Cancer Res; 2021 Mar; 10(3):1536-1556. PubMed ID: 33889528
[TBL] [Abstract][Full Text] [Related]
17. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
[TBL] [Abstract][Full Text] [Related]
18. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
19. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
20. Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
Shi M; Ma J; Feng M; Liang L; Chen H; Wang T; Xie Z
Cancer Genet; 2021 Aug; 256-257():62-67. PubMed ID: 33905998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
